Legal Representation
Attorney
Jeff Goehring
USPTO Deadlines
Next Renewal Deadline
1310 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-02-07)
Due Date
February 07, 2029
Grace Period Ends
August 07, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
22 eventsDate | Code | Type | Description |
---|---|---|---|
Feb 7, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
Feb 7, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
Jan 6, 2023 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
Jan 5, 2023 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
Dec 21, 2022 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
Dec 19, 2022 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
Dec 1, 2022 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
Dec 1, 2022 | IUAF | S | USE AMENDMENT FILED |
Jun 7, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
Apr 12, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION |
Apr 12, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Mar 23, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Mar 3, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
Mar 2, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
Mar 1, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Mar 1, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Dec 28, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN |
Dec 28, 2021 | GNRT | F | NON-FINAL ACTION E-MAILED |
Dec 28, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Dec 27, 2021 | DOCK | D | ASSIGNED TO EXAMINER |
Aug 2, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
May 1, 2021 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Medical, pharmaceutical and surgical products for nucleic acid implants of the spine, namely, carbonate apatite anorganic bone mineral for more optimal resorption and remodeling due to increased solubility, bioactive glass and highly purified bovine-derived Type I collagen; chemical substances for nucleic implants, namely, carbonate apatite anorganic bone mineral for more optimal resorption and remodeling due to increased solubility, bioactive glass and highly purified bovine-derived Type I collagen; filling substances for nucleic implants, namely, carbonate apatite anorganic bone mineral for more optimal resorption and remodeling due to increased solubility, bioactive glass and highly purified bovine-derived Type I collagen; bio-absorbable filling substances for nucleic implants, namely, carbonate apatite anorganic bone mineral for more optimal resorption and remodeling due to increased solubility, bioactive glass and highly purified bovine-derived Type I collagen; injectable viscoelastic substances for nucleic implants, namely, carbonate apatite anorganic bone mineral for more optimal resorption and remodeling due to increased solubility, bioactive glass and highly purified bovine-derived Type I collagen; injectable dermal filler in the nature of biocompatible silicone for nucleic acid implants
First Use Anywhere:
Sep 1, 2022
First Use in Commerce:
Sep 1, 2022
Class 010
Surgical nucleic implants for vertebrae; surgical nucleoarthoplasty implants for vertebrae; surgical nucleic implants based on filling substances for vertebrae; surgical implants for intervertebral discs; surgical nucleic implants based on injectable biocompatible silicone; surgical implants for intervertebral discs; surgical implants based on bone substitutes; bone substitutes, intervertebral bone substitutes, allograft bone substitutes, synthetic bone substitutes
First Use Anywhere:
Sep 1, 2022
First Use in Commerce:
Sep 1, 2022
Classification
International Classes
005
010